The Inertia Tax: Why "Wait and See" is Biotech’s Most Expensive Strategy

"Indecision is the quiet thief of destiny."

At a recent dinner hosted by Owkin in Boston, this psychological insight served as the backdrop for a candid conversation among biotech C-suites, computational scientists, and data architects. The power of AI aside, the discussion revolved around the paralysis that prevents its adoption.

Striking behavioral finding: when risks increase, decisive leaders move faster; and yet, indecisive ones often remain frozen, unresponsive to the mounting costs of delay.

In the world of drug discovery, the delay cost is real. Here are three pragmatic takeaways from the table:

• For mid-cap biotechs, the only AI value proposition that truly moves the needle is time-reduction. If a tool can cut a discovery timeline from 12 months to 6, it changes the entire narrative for investors and acquisition targets. Yet, the need for certainty keeps many leadership teams from pulling the trigger.
• AI adoption fails when it is only top-down (mandates without tools) or only bottom-up (tools without sponsorship). Successful firms are bridging the gap by pairing technical leaders with C-suite leaders who view data governance as a prerequisite for moving to next level.
• While the industry chases World Models and the next frontier of LLMs, the ground-level struggle remains data silos. Data is scattered across hospital systems, CROs, and old infrastructure, often in formats that were never built to work together. Overcoming that requires pipelines that can structure data to make it AI ready and AI models that can integrate information across different formats and modalities.

The technology is evolving faster than the organizations using it. The winners won’t necessarily be the ones with the most sophisticated models, but the ones who can overcome the habit of hesitation. That’s going to make ease of adoption a key factor - deployment and interoperability will be hygiene factors for any AI scientist.

We are having these conversations all the time, including at events in San Francisco, Zurich and Paris, to learn more about what it takes to move from insight into action. We look forward to bringing those learnings together and sharing them.